Injection drug use (IDU) is a known risk factor for hepatitis C virus (HCV) infection, but the strength of other parenteral and sexual risk factors is unclear. In 1997, we performed a case-control study of 2,316 HCV-seropositive blood donors and 2,316 seronegative donors matched on age, sex, race/ethnicity, blood center, and first-time versus repeat-donor status. Odds ratios (OR) and 95% confidence intervals (CIs) were calculated using conditional logistic regression. Questionnaires were returned by 758 (33%) HCV ؉ and 1,039 (45%) control subjects (P ‫؍‬ .001). The final multivariate model included only the following independent HCV risk factors: IDU (OR ‫؍‬ 49.6; 95% CI: 20.3-121.1), blood transfusion in non-IDU (OR ‫؍‬ 10.9; 95% CI: 6.5-18.2), sex with an IDU (OR ‫؍‬ 6.3; 95% CI: 3.3-12.0), having been in jail more than 3 days (OR ‫؍‬ 2.9; 95% CI: 1.3-6.6), religious scarification (OR ‫؍‬ 2.8; 95% CI: 1.2-7.0), having been stuck or cut with a bloody object (OR ‫؍‬ 2.1; 95% CI: 1.1-4.1), pierced ears or body parts (OR ‫؍‬ 2.0; 95% CI: 1.1-3.7), and immunoglobulin injection (OR ‫؍‬ 1.6; 95% CI: 1.0-2.6). Although drug inhalation and a high number of lifetime sex partners were significantly more common among HCV seropositives, they were not associated with HCV after controlling for IDU and other risk factors. IDU, blood transfusion among non-IDU, and sex with an IDU are strong risk factors for HCV among United States blood donors. Weaker associations with incarceration, religious scarification, being stuck or cut with a bloody object, pierced ears or body parts, and immunoglobulin injection must be interpreted with caution. (HEPATOLOGY 2000;31:756-762.)Since the discovery of hepatitis C virus (HCV) was reported in 1989, much has been learned about its epidemiology and pathogenesis. HCV seroprevalence in the general population ranges from 1% to 2% in a number of countries including the United States 1-3 to 12.6% in parts of Italy, 4 and 14.1% in areas of Japan. 5 As a result of selection for those at low risk of infectious disease, HCV prevalence is lower among blood donors, ranging from 0.06% to 1.3% in several countries, and 0.4% in the United States. [6][7][8][9][10] It is hyperendemic among injection drug users (IDUs) in industrialized countries, with infection rates of up to 90%, 11,12 consistent with the high frequency of parenteral blood exposures in this subgroup. Most HCV seropositives have persistent viremia, more than half have chronic hepatitis, and cirrhosis may occur in up to 20%. 13 Other investigators have implied that up to 40% of HCV seropositives do not have recognized parenteral risk factors, 14 leading to speculation that other as-yet-undiscovered modes of transmission may exist. Whether heterosexual transmission occurs at more than a negligible rate is also controversial. [15][16][17][18] Furthermore, a recent study reported that intranasal inhalation of cocaine appeared to be a risk factor for HCV infection in United States blood donors. 19 Clarification of the risk factors for and transmiss...

Strategies aimed at encouraging current donors to donate more frequently during the first year may help to establish a regular donation behaviour.

Time to return for second donation was associated with total number of donations made and with return rate for subsequent returns. Age was the strongest predictor of high donation frequency and early-return rate. Relationships between interdonation interval and the number of future donations may prove useful in understanding return behavior and developing donor recruitment and retention strategies.

As a part of a major study on the pathophysiologic indices for recurrence of human breast cancer, preoperative eosinophil and lymphocyte counts were determined on 419 and 581 primary breast cancer patients, respectively. Patients with lymphocyte counts less than or equal to 1500/mm3 and/or eosinophil counts of less than 55/mm3 had significantly higher risk of recurrent disease than those patients who had normal or high levels of eosinophils and/or lymphocytes. These findings may indicate that the immunologic activities of eosinophils and lymphocytes enhance the patients' ability to respond against disease. Cancer 52:126‐130, 1983.

These data suggest that efforts to improve donors' perceptions of their donation experience, as well as attention to the physical effects of blood donation, may aid in the retention of both repeat and first-time donors.

No abstract

Human T-lymphotropic virus types I and II (HTLV-I and -II) cause myelopathy; HTLV-I, but not HTLV-II, causes adult T-cell leukemia. Whether HTLV-II is associated with other diseases is unknown. Using survival analysis, we studied medical history data from a prospective cohort of HTLV-I– and HTLV-II–infected and –uninfected blood donors, all HIV seronegative. A total of 152 HTLV-I, 387 HTLV-II, and 799 uninfected donors were enrolled and followed for a median of 4.4, 4.3, and 4.4 years, respectively. HTLV-II participants had significantly increased incidences of acute bronchitis (incidence ratio [IR] = 1.68), bladder or kidney infection (IR = 1.55), arthritis (IR = 2.66), and asthma (IR = 3.28), and a borderline increase in pneumonia (IR = 1.82, 95% confidence interval [CI] 0.98 to 3.38). HTLV-I participants had significantly increased incidences of bladder or kidney infection (IR = 1.82), and arthritis (IR = 2.84). We conclude that HTLV-II infection may inhibit immunologic responses to respiratory infections and that both HTLV-I and -II may induce inflammatory or autoimmune reactions.

No abstract